Abstract. Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer with poor responsiveness to existing drug therapies. Therefore, novel treatment strategies against ICC are required to improve survival. The aim of this study was to demonstrate the role of fused-inglioblastoma-c-ros-oncogene1 ( 
Introduction
Intrahepatic cholangiocarcinoma (ICC) has become the second most common primary liver cancer, representing 10-25% of cases, with poor responsiveness to existing drug therapies (1) . Liver transplantation is useful in the treatment of cholangiocarcinoma. However, recurrence of the disease is common due to the unique biological characteristics involved, such as cholangiocyte differentiation and abundant stromal desmoplasia. Due to the lack of an early diagnosis, most patients are not eligible for surgical resection (2) (3) . Therefore, novel treatment strategies against ICC are needed to improve survival, particularly in high-risk subgroups.
Although many frequently mutated genes have been identified in cholangiocarcinoma, such as TP53 (37-44%) and KRAS (17-54%) (4), none of these signature genes have become targets of therapy. Sequencing efforts are continuously conducted in order to generate in-depth information with regard to the somatic alterations in ICC. Receptor tyrosine kinases (RTKs), the important mediators of extracellular signals, regulate key cell growth, survival, and motility pathways. In various types of cancer, dysregulated RTK activation was found in the process of initiation and progression. Recently, the oncogenic mutations of the orphan RTK c-ros oncogene (ROS) fusion genes was found in almost 9% of cholangiocarcinoma patients (5) . Several ROS kinase fusion proteins have been identified, including the fused-inglioblastoma-ROS1 (FIG-ROS) , SLC34A2-ROS1 (SLC-ROS), CD74-ROS1, EZR-ROS1, LRIG3-ROS1, SDC4-ROS1, and TPM3-ROS1 (5). FIG-ROS was first identified in a human glioblastoma cell line (6) and more recently in patients with ICC (5) . In animal models, FIG-ROS has been validated as a potent oncoprotein in ICC (7) . In clinical application, anaplastic lymphoma kinase (ALK) kinase is mostly homologous with ROS. Phase I/II clinical trials have focused on the ALK inhibitor crizotinib for its efficacy in ROS1-driven lung cancer patients, leading to its approval by the Food and Drug Administration (FDA) (8 
Materials and methods
Tissue specimen collection. Study protocols were approved by the Ethics Committee of the Third Xiangya Hospital, Central South University (Hunan, China). Four ICC tissues and three normal tissues were obtained at the Department of General Surgery of the Third Xiangya Hospital of Central South University. Informed consent was obtained from patients. Tissues were immediately frozen in liquid nitrogen following surgical removal.
Immunohistochemistry. Tissues were fixed in formalin, sectioned and mounted on poly-l-lysine-coated glass slides. Paraffin sections were deparaffinized, and incubated in antigen retrieval buffer for 2 min at 95̊C and then for 10 min at room temperature. The sections were then treated in 3% hydrogen peroxide for 5 min. Non-specific antibody binding was blocked with 5% BSA in TBST. The sections were treated with mouse anti-ROS1 monoclonal antibody (Abcam, Cambridge, UK) overnight at 4̊C in PBS, rinsed, and subsequently incubated for 1 h with biotinylated HRP-conjugated goat anti-mouse secondary antibody (Abcam), followed by the avidin-biotin complex (Dako, Copenhagen, Denmark). The sections were developed with DAB, counterstained with hematoxylin, and examined under a microscope (DM1750M; Leica, Solms, Germany) to assess the immunoreactivity.
Cell lines and cell culture. Human ICC cell lines, HUCCT1, RBC, and QBC939, were purchased from ATCC. Cells were cultured in DMEM and 10% fetal bovine serum (FBS) was added at 37̊C in a humidified incubator containing 5% CO 2 . Table I . HUCCT1 cells were transfected with these plasmids, respectively, using Lipofectamine 2000 (Invitrogen Life Technologies, Shanghai, China) according to the manufacturer's instructions. Subsequently, the cells were incubated at 37̊C with 5% CO 2 for 72 h using MTT assay.
Western blotting. Tissues or cells were solubilized in cold RIPA lysis buffer. Proteins were separated with 12% SDS-PAGE, and transferred onto a polyvinylidene difluoride (PVDF) membrane. The membrane was incubated with TBST containing 5% skimmed milk at 37̊C for 2 h. The membrane was then incubated with rabbit anti-ROS, rabbit anti-FIG, and mouse anti-GAPDH primary antibodies (all from Santa Cruz Biotechnology, Inc., Santa Cruz, USA), respectively, at room temperature for 2 h. After washing with PBST 4 times for 10 min each time, the membrane was incubated with the goat anti-rabbit and goat antimouse secondary antibodies (Santa Cruz Biotechnology, Inc.) at 4̊C overnight. After washing with PBST 4 times for 10 min each time, an ECL kit (Pierce Chemical, Rockford, IL, USA) was used to perform chemiluminent detection. Image-Pro plus software 6 .0 was used to analyze the relative protein expression, represented as the density ratio versus GAPDH. GAPDH was used as an internal reference.
Cell proliferation assay. MTT assay was used to measure cell proliferation. At 72 h post-transfection, 100 µl cell suspension (1x10 5 cells/ml) was seeded into 96-well plates, and incubated at 37̊C with 5% CO 2 for 0, 1, 3, 5 and 7 days, respectively. For the MTT assay, the transfection medium in each well was replaced by 100 µl of fresh serum-free medium with 0.5 g/l MTT. After incubation at 37̊C for 4 h, the MTT medium was removed by aspiration and 50 µl of DMSO was added to each well. After reacting for 10 min at room temperature, formazan production was detected by measurement of the optical density (OD) at 570 nm using a Bio-Tek ELx-800 type ELISA reader (BioTek, Winooski, VT, USA). This assay was repeated 3 times.
Cell apoptosis assay. For cell apoptosis assay, 1x10
6 cells were collected, washed twice with cold phosphate-buffered saline (PBS), and then resuspended in 500 µl 1X binding buffer. Annexin V-FITC (5 µl) and propidium iodide (PI; 5 µl) were added to the solution and mixed well. After incubation for 15 min at room temperature in the dark, the cells were analyzed using FACSCalibur flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA).
Cell cycle assay. For all groups, 1x10
6 cells were collected in PBS and fixed in 70% ethanol overnight at -20˚C. The cells were pelleted at 1,000 rpm/min for 5 min, washed in PBS, and then pelleted at 1,000 rpm/min for 5 min. Cells were resuspended in 300 µl propidium iodide staining buffer and incubated for 30 min at room temperature. DNA content 
analyses were performed using FACSCalibur flow cytometry (BD Biosciences). This assay was repeated 3 times.
Colony formation assay. For each group, 4 ml complete medium containing 200 cells was added to a 60-mm dish.
Following cell culture at 37̊C with 5% CO 2 for 14 days, the supernatant was discarded, and the cells were washed with PBS 3 times. The cells were then fixed with 4% paraformaldehyde for 15 min, and stained with GIMSA (Solarbio, Beijing, China) for 20 min. Colonies were counted under an inverted microscope (Nikon, Tokyo, Japan). This assay was repeated 3 times.
Cell migration assay. Corning-Costar 3494 Transwell (Corning Life Sciences, Oneonta, NY, USA) was used to perform cell migration assay, according to the manufacturer's instructions. In brief, cell suspension (5x10 5 cells/ml) was prepared in serum-free DMEM. For each group, 500 µl of DMEM with 10% FBS was added into the lower chamber, and 300 µl of cell suspension was added into the upper chamber. After incubation at 37̊C with 5% CO 2 for 24 h, the cells that did not migrate through the membrane were gently removed. Cells that migrated through the membrane were stained for 20 min, rinsed in water, and air dried. Six fields were randomly selected under the microscope (Nikon), and the stained cell number was counted. This assay was repeated 3 times.
Cell invasion assay. For the cell invasion assay, 24-well Transwell chambers (Chemicon, Temecula, CA, USA) with a layer of matrix gel were used. For each group, cell suspension (5x10 5 cells/ml) was prepared in serum-free DMEM, and 500 µl of DMEM with 10% FBS was added into the lower chamber, and 300 µl of cell suspension was added into the upper chamber. After incubation at 37̊C with 5% CO 2 for 24 h, the non-invading cells and matrix gel were removed, and the same procedure described above was performed.
Statistical analysis. Data are expressed as mean ± SD of three independent experiments. SPSS.13.0 software was used to perform statistical analysis. Differences were analyzed using one-way analysis of variance (ANOVA) or two-way ANOVA. P<0.05 was considered statistically significant.
Results

Positive expression of ROS in ICC tissues and HUCCT1 cells.
To determine the role of ROS in ICC, we firstly performed immunohistochemistry and western blotting to determine the protein expression of ROS in ICC tissues as well as in the ICC cell lines, HUCCT1, REB, and QBC939. As demonstrated in Fig. 1A , one ICC sample showed a positive expression of ROS, while none of the normal samples showed any positive expression of ROS. Furthermore, we found that ROS was positively expressed in HUCCT1 cells. However, we did not detect ROS expression in the REB and QBC939 cell lines (Fig. 1B) . Accordingly, the HUCCT1 cell line was used in subsequent experiments. or FIG-363 shRNA plasmid, or both. As shown in Fig. 3 , single downregulation of FIG had no effect on HUCCT1 cell proliferation; however, the shRNA-mediated downregulation of ROS or ROS+FIG effectively inhibited the proliferation of HUCCT1 cells. Moreover, our findings showed that co-downregulation of ROS and FIG had an improved inhibitory effect on HUCCT1 cell proliferation, compared to the single downregulation of ROS (Fig. 3) .
shRNA-mediated downregulation of ROS-FIG
Effects of shRNA-mediated ROS-FIG downregulation on HUCCT1 cell apoptosis.
Since the downregulated cell proliferation induced by ROS-and FIG-specific shRNAs may be attributed to the occurrence of cell apoptosis, we determined the cell apoptotic rate by using PI/Annexin V staining and flow cytometry. Fig. 4 shows that the shRNA-mediated downregulation of FIG had no effect on HUCCT1 cell apoptosis. However, single downregulation of ROS or co-inhibition of (Fig. 4) . These findings suggest that ROS-and FIG-specific shRNA-mediated downregulation of HUCCT1 cell proliferation was partially at least due to the induction of cell apoptosis.
Effects of shRNA-mediated ROS-FIG downregulation on cell the cycle progression of HUCCT1 cells.
As the shRNA-mediated downregulation of HUCCT1 cell proliferation may also be due to the abnormal cell cycle progression, we examined the cell cycle distribution in each group using PI staining and flow (Fig. 6) . The data demonstrated that the suppressive rate was ROS+FIG shRNA > ROS shRNA > FIG shRNA (Fig. 6) . (Fig. 8) . However, single inhibition of FIG showed no effect. In addition, unlike the cell migration data, the co-inhibition of ROS and FIG did not show a stronger suppressive effect on cell invasion, compared with single inhibition of ROS.
Effects of shRNA-mediated ROS-FIG downregulation
ROS-FIG downregulation inhibited the activity of Akt signaling.
To assess the molecular mechanism by which ROS-FIG downregulation affected HUCCT1 cell proliferation, apoptosis, and cell cycle progression, we examined the activity of Akt signaling, which has been demonstrated to be upregulated in various types of cancer including ICC (9) . Single inhibition of ROS or co-inhibition of ROS and FIG notably suppressed the activity of Akt signaling in HUCCT1 cells (Fig. 9) . Moreover, the co-inhibition of ROS and FIG showed a stronger inhibitory effect when compared to single inhibition of ROS. 
Discussion
Cholangiocarcinoma, an aggressive and lethal cancer, originates from the neoplastic transformation of the intra-and extra-hepatic bile ducts epithelial cells (10) . Morphologically, ICCs were classified as mass-forming, periductular infiltrating, or intraductal growth pattern (11) (12) . Numerous risk factors promote the development of ICC. ROS fusions were identified originally in glioblastoma and non-small cell lung cancer (NSCLC) to promote their progression (13) (14) . The oncogenic activation of ROS1 was observed in a subset of patients with cholangiocarcinoma, glioblastoma and lung cancer (5-6,15) . Wild-type full-length ROS1 is a 2,347 amino acid transmembrane tyrosine kinase (TK) receptor, consist ing of an extracellular ligand-binding domain composed of nine repeated fibronectin-like motifs, an intracellular TK domain, and a short transmembrane domain (16) . Dysregulated ROS1 may occur in different types, including ROS1 gene fusion, overexpression, or mutations. In many cases, the ROS1 pathway was activated by interchromosomal translocation or intrachromosomal deletion, which resulted in N-terminal ROS1 fusion genes. Increasing evidence (20) has shown that ROS1 fusions as a distinct subgroup within various types of cancer promoted the development of ROS1-directed therapeutic strategies.
Of the four ICC samples we collected from our hospital, only one showed a positive protein expression for ROS. 0.7% (11/1,476) of ROS fusions among lung cancer patients was observed in Japan (13) . A low expression of FIG-ROS fusions in Chinese ICC patients was identified in our study, which is in accordance with previous studies (5) . This low expression should be considered as important. Although rare, emerging evidence supports ROS fusions as a valid therapeutic target in molecularly defined patients. In malignant gliomas, the demethylation of ROS promoter enhanced the elevated expression of ROS kinase (17) . Chromosomal rearrangements involve ROS kinase in glioblastoma and NSCLC (6, 18) . Apoptosis is a type of cell death that is characterized by a series of morphologic changes, and plays an important role in the development and tissue homeostasis of cells. Promotion of apoptosis is the ultimate goal of preventive strategies for cancer (21) Recently, Davies et al suggested that EGFR pathway activation mediated resistance to ROS1 inhibition in NSCLC (23) . Aberrant ROS1 kinase activity resulted in the activated downstream signaling of several oncogenic pathways, including AKT/mTOR, RAS-MAPK/ERK, and Src-homology 2 domaincontaining phosphatase (SHP)-1 and -2 pathways (19, 24) . Moreover, Akt signaling has been shown to control cell proliferation, survival, and cell cycle progression and is aberrantly upregulated in various types of cancers including ICC (25, 26) . Accordingly, we examined the activity of Akt signaling, and showed that the co-inhibition of ROS and FIG exerted a stronger inhibitory effect on Akt signaling activity when compared to single inhibition of ROS.
In conclusion, this study confirmed that FIG-ROS fusion as a potent oncoprotein in ICC. Specifically, downregulated ROS1-6290 segment mediated by shRNA exhibited a stronger inhibitory effect on HUCCT1 cell proliferation. Downregulation of FIG showed a synergistic effect with ROS1. Therefore, the ROS1 inhibitors directed to ROS1-6290 segment may be an effective strategy for a subset of human ICC harboring ROS1 fusion proteins.
